These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 27919491)

  • 1. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of ozanimod
    Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M
    Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Iljicsov A; Pál Z; Simó M
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
    Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
    Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.